Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 06 Jun 2017 Results of interim analysis (n=27) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Feb 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
- 03 Aug 2015 Planned primary completion date changed from 1 Sep 2017 to 1 Jul 2017 as reported by Clinicaltrials.gov record.